Researchers delve into the current understanding of the clinical course and treatment of AATD, offering a comprehensive overview of the disease. In an ambitious overview of the documented developments ...

INBRX-101 is a recombinant human AAT-Fc fusion protein designed to replace the enzyme that is deficient in AATD and offer less frequent dosing than current therapies for the disease, based on ...

It is a time to draw awareness to the issues that AATD brings to the table. This year, I want to share my realization that self-preservation is very much okay, especially in those with chronic health ...

Methods The study population included 21 severe AATD (ZZ), 22 moderate AATD (MZ) and 23 non-AATD (MM) individuals, further categorised as healthy, unobstructed current smokers or patients with chronic ...

Mereo BioPharma targets osteogenesis imperfecta market growth with setrusumab. Discover why MREO stock is well-positioned for ...

Korro Bio has secured approvals in Australia to commence the Phase I/IIa trial of KRRO-110, aimed at treating AATD.

Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from ...

A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available ...

There are an estimated 200,000 individuals living with AATD in the US and Europe with this genetic form of the disease. M-ATT levels were below the limit of detection at baseline, but rose to ...

Setrusumab receives Breakthrough Therapy designation from the FDACash of $80.5 million as of September 30, 2024, expected to fund operations into ...